CLPH-291 is under clinical development by Cellphire and currently in Phase II for Wiskott-Aldrich Syndrome. According to GlobalData, Phase II drugs for Wiskott-Aldrich Syndrome have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CLPH-291’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CLPH-291 overview
CLPH-291 is under development for the treatment of Glanzmann’s thrombasthenia, Bernard-Soulier syndrome, Hermansky-Pudlak syndrome, and Wiskott-Aldrich syndrome. It is being developed based on FPH (freeze-derived platelet-derived hemostat) technology.
Cellphire overview
Cellphire is a biotechnology company developing next-generation allogeneic, platelet-derived, cellular therapeutics. Its product portfolio includes CLPH-511, a freeze-dried platelet-derived hemostat (FPH), and CLPH-211 for the indication of platelet substitutes, perioperative hemorrhage, and dual antiplatelet therapy bleeding. Cellphire also developing CLPH-291 and CLPH-251 for the indication of rare genetic HLA compatible and intercranial hemorrhage (traumatic intracranial hemorrhage, spontaneous intracerebral hemorrhage, and mild traumatic brain injury). thrombosomes are used to treat and stop internal bleeding. Its products are used in hospital operating rooms. Cellphire is headquartered in Rockville, Maryland, the US.
For a complete picture of CLPH-291’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
